Experimental HCV Drugs
Experimental HCV Drugs
AASLD 2013: Fixed-dose Sofosbuvir/Ledipasvir Cures Most Genotype 1 Hepatitis C
- Details
- Category: Experimental HCV Drugs
- Published on Monday, 11 November 2013 00:00
- Written by Liz Highleyman
At least 95% of newly treated genotype 1 hepatitis C patients and prior non-responders achieved sustained virological response using a fixed-dose combination of sofosbuvir plus ledipasvir, with or without ribavirin, according to findings from the LONESTAR study presented the 64th AASLD Liver Meeting last week in Washington, DC. While response rates were high overall, the 2 relapsers in the trial were not taking ribavirin.
AASLD 2013: Sofosbuvir + Ribavirin for 12 or 24 Weeks Cures Most Genotype 2-3 Hepatitis C Patients
- Details
- Category: Experimental HCV Drugs
- Published on Monday, 11 November 2013 00:00
- Written by Liz Highleyman
A dual oral regimen of sofosbuvir plus ribavirin led to sustained response for 93% of genotype 2 hepatitis C patients treated for 12 weeks and 85% of genotype 3 patients treated for 24 weeks, researchers reported last week at the 64th AASLD Liver Meeting in Washington, DC. A related study found that adding ribavirin to this combination may be an option for harder-to-treat individuals.
AASLD 2013: Simeprevir with Pegylated Interferon/ Ribavirin Cures Genotype 1 Hepatitis C in 80%
- Details
- Category: Experimental HCV Drugs
- Published on Monday, 11 November 2013 00:00
- Written by Janssen
Simeprevir added to pegylated interferon and ribavirin performed well in difficult-to-treat treatment-naive patients and prior relapsers with genotype 1 chronic hepatitis C, according to 2 poster presentations at the 64th AASLD Liver Meeting last week in Washington, DC, as described in an announcement by Janssen.
AASLD 2013: Daclatasvir + Asunaprevir Cures 85% of Genotype 1b Hepatitis C Patients in Japanese Study
- Details
- Category: Experimental HCV Drugs
- Published on Monday, 11 November 2013 00:00
- Written by Liz Highleyman
An interferon- and ribavirin-free oral regimen of daclatasvir plus asunaprevir taken for 24 weeks led to sustained virological response in 85% of Japanese patients with hepatitis C virus subtype 1b, according to findings presented at the 64th AASLD Liver Meeting last week in Washington, DC.
AASLD 2013: Sofosbuvir Taken Before or After Liver Transplant Reduces HCV Recurrence
- Details
- Category: Experimental HCV Drugs
- Published on Friday, 08 November 2013 00:00
- Written by Liz Highleyman
An interferon-free combination of sofosbuvir plus ribavirin administered before liver transplantation prevented hepatitis C recurrence in nearly two-thirds of patients, while the same regimen led to early viral clearance in three-quarters of those treated after transplantation, according to studies presented this week at the 64thAASLD Liver Meeting in Washington, DC.
More Articles...
- AASLD 2013: Merck Interferon-free Regimen Shows High Hepatitis C Cure Rate in Early Study
- AASLD 2013: BMS Interferon-free Combo Cures Over 90% of Genotype 1 HCV in 12 Weeks
- AASLD 2013: AbbVie's Dual Interferon-free Combination Cures Genotype 1b Hepatitis C in 95%
- AASLD 2013: 100% of Hard-to-treat Patients Cured with Sofosbuvir/Ledipasvir + Ribavirin or GS-9669
Web Design and Development by